M&T Bank Corp Decreases Stake in United Therapeutics Corporation (NASDAQ:UTHR)

M&T Bank Corp cut its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 28.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,464 shares of the biotechnology company's stock after selling 965 shares during the quarter. M&T Bank Corp's holdings in United Therapeutics were worth $760,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of UTHR. Cerity Partners LLC increased its position in shares of United Therapeutics by 30.4% during the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after purchasing an additional 2,702 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 376 shares in the last quarter. Korea Investment CORP raised its stake in United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after acquiring an additional 2,300 shares during the period. Concurrent Investment Advisors LLC bought a new position in shares of United Therapeutics in the first quarter worth approximately $227,000. Finally, Nepsis Inc. boosted its holdings in United Therapeutics by 6.7% in the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock worth $18,057,000 after buying an additional 3,653 shares during the period. Institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 645 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the transaction, the director owned 4,883 shares in the company, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Raymond Dwek sold 3,000 shares of United Therapeutics stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $285.57, for a total value of $856,710.00. Following the completion of the transaction, the director owned 1,750 shares of the company's stock, valued at approximately $499,747.50. This represents a 63.16% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 84,681 shares of company stock valued at $25,261,669. Insiders own 10.30% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Morgan Stanley decreased their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. HC Wainwright restated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. UBS Group decreased their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Finally, Bank of America decreased their target price on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average price target of $383.08.

United Therapeutics Stock Down 1.5%

Shares of NASDAQ UTHR traded down $4.44 during trading hours on Tuesday, hitting $293.24. 303,168 shares of the stock were exchanged, compared to its average volume of 443,618. The firm has a fifty day moving average price of $301.04 and a 200-day moving average price of $319.73. The company has a market cap of $13.23 billion, a PE ratio of 11.70, a PEG ratio of 6.46 and a beta of 0.53. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company's revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.17 earnings per share. As a group, equities analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.